Temsirolimus (Table 1) is the other small molecule inhibitors of mTOR, and part of the PI3K/AKT pathway involved in tumor cell proliferation and angiogenesis approved by FDA for advanced RCC. This evidence concerns the gene AKT1 and neoplasm.